Heranostic radiopharmaceuticals

Love Employee/iStock via Getty Images

  • Privately held Radionetics Oncology, which is focused on small molecule G protein coupled receptor (GPCR) targeted radiopharmaceuticals for tumors, could receive more than $1B under an agreement with Eli Lilly (NYSE:LLY).
  • The pharma giant has provided Radionetics with a $140M upfront payment

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Posts